Stock Monitor: CHF Solutions Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BSX as the Company's latest news hit the wire. On April 16, 2018, the Company announced the acquisition of privately owned nVision Medical Corporation. nVision is a company that has the distinction of developing the first and only device approved by the US Food and Drug Administration (FDA) that can help doctors in earlier diagnosis of ovarian cancer. The cash plus milestone payments-based deal is valued approximately $275 million. The acquisition is aimed at expanding the Company's women's health portfolio. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for CHF Solutions, Inc. (NASDAQ: CHFS), which also belongs to the Healthcare sector as the Company Boston Scientific. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Boston Scientific most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
San Bruno, California-based nVision was founded by Surbhi Sarna in 2011 to fill the void in women's health. She was on the Forbes' 30 Under 30 list In Healthcare in 2014.
Details of the deal
As per the terms of acquisition, Boston Scientific has agreed to pay $150 million as upfront cash payment with additional $125 million payable on achieving pre-agreed clinical and commercial milestones over the next four years. Boston Scientific does not expect the acquisition to have an impact on its earnings in FY18 and FY19; however, the Company expects the deal to be accretive on an adjusted basis thereafter. The Company expects that the deal will be dilutive to its earnings on GAAP basis till 2020 and later less accretive due to costs related to amortization expense and acquisition.
Commenting on the acquisition of nVision, Dave Pierce, EVP and President – MedSurg at Boston Scientific, said:
"We are committed to expanding our women's health portfolio and driving clinical research that will help deliver innovative options for the prevention and treatment of gynecological cancer."
Surbhi Sarna, founder and CEO of nVision, added:
"I am proud of our achievements in advancing efforts to help with the early detection of ovarian cancer and look forward to working with Boston Scientific to move this technology forward."
About Ovarian Cancer and nVision's device
nVision's Mako 7 is a that uses patented microcatheter technology to access and collect cells from the fallopian tube during a minimally-invasive hysteroscopic procedure. These cell samples can then be further analyzed by cytologists. This device received FDA clearance in June 2016. nVision is also in the process of developing a visualization device that leverages its microcatheter technology to enable direct visualization of fallopian tubes during hysteroscopy using a small fiberscope.
Studies conducted on ovarian cancer have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes. Ovarian cancer is said to be the fifth major cause of cancer related deaths in women. As per a rough estimate over 2 million US women are at a high risk of developing ovarian cancer, especially those whose families have a history of BRCA1 or 2 gene mutations. Alarmingly, ovarian cancer has no symptoms in the early stages and even in the later stages of the disease, the symptoms can be very non-specific, viz., loss of appetite and weight loss. So far there are no recommended early screening tests available plus there has been no effective way to biopsy cells in the fallopian tubes. Due to these reasons, nearly 300,000 women elect to remove their ovaries and fallopian tubes every year to reduce the risk of developing ovarian cancer. However, the removal leads to other risks like developing cardiovascular issues, cognitive impairment and prevents child bearing. This is where nVision's device will help women in making informed choices.
The initial clinical research on nVision's device shows that the device can effectively collect cells from the fallopian tubes. These cells when tested correlate with a post-surgery definitive diagnosis of ovarian cancer. Boston Scientific has plans to conduct further clinical research on nVision's device to prove that the cells collected from the fallopian tubes can be used in making early diagnosis before conducting surgery. This will enable women with increased risk of ovarian cancer in making educated decisions.
The device is expected to have a market opportunity of $500 million in the near-term and has the potential to reach $2 billion as it gains popularity and more gynecologists relyoin the device to help women make decisions.
About Boston Scientific Corp.
Marlborough, Massachusetts-based Boston Scientific is a global medical technology company dedicated to transforming lives through innovative medical solutions that improve the health of patients worldwide. The Company has been working for more than 35 years to provide a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. The Company has over 13,000 life changing products and has presence in over 100 countries with operational sales of over $8.4 billion.
Stock Performance Snapshot
April 17, 2018 - At Tuesday's closing bell, Boston Scientific's stock slightly climbed 0.10%, ending the trading session at $28.86.
Volume traded for the day: 9.78 million shares, which was above the 3-month average volume of 7.49 million shares.
Stock performance in the last month – up 3.33%; previous three-month period – up 6.97%; past twelve-month period – up 17.22%; and year-to-date - up 16.42%
After yesterday's close, Boston Scientific's market cap was at $39.70 billion.
Price to Earnings (P/E) ratio was at 41.47.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 0.9% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.